Study details
Enrolling now
Impact of Early Aging and Menopause on Vascular Responses to Hypoxia
University of Missouri-Columbia
NCT IDNCT06417177ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
75
Study length
about 2.2 years
Ages
18–70
Sex
Female only
Locations
1 site in MO
About this study
Researchers are testing how aging, menopause, and hypoxia affect blood vessels. The trial will evaluate the role of beta-adrenergic receptors in women experiencing these conditions. Participants will receive either Gemtesa, a placebo, or Propranolol.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Gemtesa
- 2.Take Placebo
- 3.Take Propranolol
PhaseEARLY_Phase 1
DrugPropranolol
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
propranolol (Non-selective beta blocker; slows heart rate)
Body systems
Reproductive Health